녹아웃(KO) 마우스 | Cyagen Korea

3rd Annual Genome Editing Congress 2017

Date: Nov 09, 2017


Over 600 senior-level delegates representing internationally renowned research & academic institutions, clinical research institutions, nutrition companies as well as leading pharmaceutical and biotech companies. Over 20 case studies and presentations focused on the developments in genome editing techniques and case studies on the therapeutic applications of genome editing.

Cyagen Biosciences and VectorBuilder is excited to announce that we are sponsoring the 3rd Annual Genome Editing Congress on the 9th-10th November 2017.

Dr Kristofer Müssar (Managing Director Europe) and Dr Matthew Wheeler (Associate Director Europe) will be present to address any questions you might have about our animal model generation services, vector construction services, virus packaging services, BAC modification services, or anything else at all including our free web based vector design platform, VectorBuilder.com.

Dr Matthew Wheeler will be giving a talk on Thursday 9th at 15.20:

Cyagen - World Leader in Novel Technologies for the Rapid Generation of Custom-Designed Animal Models and Vector

     ● CRISPR/Cas9 mediated mouse/rat knockouts and knockins: point mutations, Rosa26 and any locus large fragment KI 
     ● TurboKnockout®, the fastest ES cell targeting platform for generation of cKO, cKI and humanized mice 
     ● PiggyBac based transgenic mice and rats
     ● VectorBuilder.com - the only fully featured online vector tool for vector design, virus packaging, ordering, and cloning services

We hope you will have time to come and say hello at booth # 1 and pick up some fun free items for your lab like keychains, pens as well as a “Free Vector card”.

Time: 9-10th November 2017

Location: Novotel London West Hotel
                 1 Shortlands
                 Hammersmith International Ctre
                 London W6 8DR
                 UK

  • Contact Us

    영업일 기준 1-2일 내에 답변해 드리겠습니다.

    *

    The username is required

    *

    The user's email is required

    Please enter a valid email address.

    *

    The content is required

    *